Overview

Insomnia Treatment Market Introduction

Insomnia Treatment Market to value over USD 5.8 Billion by 2029 end and register a CAGR of over 5.2% from 2020 to 2029.

The growing cases of insomnia worldwide due to rising stress levels has led to the growth of this market. With rising geriatric population coupled with awareness about numerous therapies and treatments in the market, support and propel the market’s growth.

With advancements in technology and invention of better, efficient, new therapies providing quick, positive results, the public is more open to accepting such cures. Thus the increase in the launch of novel products such as Merck & Co.’s Belsomra is projected to fuel high demand. Moreover, the availability of multiple generics is expected to boost the insomnia therapeutics market over the forecast period. Lemborexant, a novel Orexin Receptor Antagonist (ORA) by Eisai is expected to be launched in the near future, which may promote growth.
With new products and technology employed the market is estimated to soar unboundedly. Additionally, quite a few medical devices have been approved in the recent years such as EBB Insomnia Therapy, Fisher Wallace Stimulator, and Alpha-Stim AID, which are expected to have higher penetration due to favourable reimbursement policies and adoption of the device-drug combination therapies for treating insomnia.

North America was leading the insomnia therapeutics market and accounted for a major revenue share. Favourable reimbursement policies will further promote revenue growth.
North America is followed by the Asia Pacific, which is poised to grow at healthy CAGR. Emerging economies such as India, China, and Indonesia have been using generics and branded generics due to the economic pricing of generic alternatives.
Asia Pacific is anticipated to witness lucrative growth over the forecast period with a high CAGR.

The global insomnia therapeutics market is highly fragmented with several manufacturers offering generics.

Major market players are:

Takeda Pharmaceutical Company Ltd.; Vanda Pharmaceuticals; Merck & Co., Inc.; Pfizer Inc.; Teva Pharmaceutical Industries Ltd.; Mylan N.V.; Sumitomo Dainippon Pharma Co., Ltd; Sanofi; Paratek Pharmaceuticals Inc.; and Ebb Therapeutics.

Insomnia Treatment Market Segmentation:
By Drug Type
• OTC Drugs
• OTC Sleep Aids
• OTC Sleep Supplements
• Prescription Drugs

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• e-Commerce
• Drug Stores
• Others

By Region:
• Europe
• North America
• APAC
• Latin America
• Rest of World

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Takeaways
• Growth prospects
• SWOT analysis
• Key trends
• Key data points affecting market growth

Objectives of the Study:
• To provide an exhaustive analysis on the global insomnia treatment market by drug type, by distribution channel and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East.
• To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
• Profiling of companies to evaluate their market shares, strategies, financials and core competencies